NVOX是追踪Novo Nordisk的2x杠杆基金,以减肥药物闻名。 Defiance ETFs launches NVOX, a 2x leveraged fund tracking Novo Nordisk, known for weight loss drugs.

NVOX是第一家以Novo Nordisk为主的有2股杠杆的ETF,一家丹麦制药公司,Novo Nordisk以减肥药物Ozempic和Wegovy闻名。 Defiance ETFs has introduced NVOX, the first 2x leveraged ETF focused on Novo Nordisk, a Danish pharmaceutical company known for its weight loss drugs Ozempic and Wegovy. NVOX向零售投资者提供比Novo Nordisk每天暴露于股票价格变化的风险翻一番,而不需要差价账户。 NVOX offers retail investors double the daily exposure to Novo Nordisk's stock price changes without needing a margin account. 尽管可能带来高回报率,但特别信托基金因其单一库存重点而面临重大风险。 Despite the potential for high returns, the ETF comes with significant risks due to its single-stock focus.